

Edgar Filing: ASTRALIS LTD - Form 10QSB

ASTRALIS LTD
Form 10QSB
August 21, 2006

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549

FORM 10-QSB

(Mark One)

☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934 For the quarterly period ended June 30, 2006.

☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934 For the transition period from _____ to _____

Commission file number: 000-30997

ASTRALIS LTD.

(Exact name of small business issuer as specified in its charter)

Delaware 84-1508866
(State or Other Jurisdiction of (I.R.S. Employer Identification No.)
Incorporation or Organization)

75 Passaic Avenue
Fairfield, New Jersey 07004
(Address of principal executive offices)
(973) 227-7168
(Issuer's telephone number)

Check whether the issuer (1) filed all reports required to be filed by
Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such
shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days.

Yes ☒ No ☐

Indicate by check mark whether the registrant is a shell company (as
defined in Rule 12b-2 of the Exchange Act).

Yes ☐ No ☒

State the number of shares outstanding of each of the issuer's classes of
common equity, as of the latest practicable date: 91,454,873 shares of Common
Stock outstanding as of August 18, 2006.

Transitional Small Business Disclosure Format (check one):

Yes ☐ No ☒

ASTRALIS LTD.

Edgar Filing: ASTRALIS LTD - Form 10QSB

INDEX

FOR THE QUARTERLY PERIOD ENDED June 30, 2006

Part I	Financial Information.....	1
Item 1	Financial Statements	
	Condensed Balance Sheets.....	1
	Condensed Statements of Operations (unaudited).....	2
	Condensed Statements of Cash Flows (unaudited).....	3
	Notes to Condensed Financial Statements (unaudited).....	4
Item 2	Management's Discussion and Analysis or Plan of Operation.....	9
Item 3	Controls and Procedures.....	11
	Risk Factors.....	12
Part II	Other Information.....	18
Item 2	Unregistered Sales of Equity Securities and Use of Proceeds.....	18
Item 6	Exhibits.....	19

PART I. FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

ASTRALIS LTD.
(A Development Stage Entity)
Condensed Balance Sheets
(Unaudited)

	ASSETS	June 30, 2006

Current Assets		
Cash and cash equivalents		\$ 55,637
Prepaid expenses		85,031
Supplies		32,110

Total Current Assets		172,778
Property and Equipment, Net		61,426
Deposits		25,000

		\$ 259,204
		=====

LIABILITIES AND STOCKHOLDERS' EQUITY

Current Liabilities		
Accounts payable and accrued expenses		\$ 273,486

Total Current Liabilities		273,486

Convertible notes, net - related party, \$350,000 face value (see Note 5)		13,802

Edgar Filing: ASTRALIS LTD - Form 10QSB

Total Liabilities	287,288
Commitments and Contingencies	
Stockholders' Equity	
Common stock; \$.0001 par value; 150,000,000 shares authorized at 2006 and 2005; 91,454,873 and 73,173,055 issued and outstanding at 2006 and 2005	9,145
Additional paid-in capital	54,410,299
Deficit accumulated in the development stage	(54,447,528)
Total Stockholders' Equity	(28,084)
	\$ 259,204

See the accompanying notes to condensed financial statements

1

ASTRALIS LTD. (A Development Stage Entity) Condensed Statements of Operations (Unaudited)

	Three Months Ended June 30,		Six Months
	2006	2005	2006
Revenues	\$ --	\$ --	\$ --
Operating Expenses			
Research and development - related party	--	--	--
Research and development	125,723	507,708	289,750
Share based compensation	36,768	--	71,876
Depreciation and amortization	2,716	6,724	5,813
General and administrative	238,845	365,288	466,755
Total Operating Expenses	405,217	879,720	835,359
Loss From Operations	(405,217)	(879,720)	(835,359)
Other (income) expense			
Investment income	(1,448)	(4,972)	(4,347)
Registration rights penalty	--	--	--

Edgar Filing: ASTRALIS LTD - Form 10QSB

	-----	-----	-----
Loss Before Income Tax Benefit	(403,769)	(874,748)	(831,012)
Income Tax Benefit	--	--	--
	-----	-----	-----
Net Loss	(403,769)	(874,748)	(831,012)
Preferred Stock Dividends	--	--	--
	-----	-----	-----
Net Loss to Common Stockholders	\$ (403,769)	\$ (874,748)	\$ (831,012)
	=====	=====	=====
Basic and Diluted Loss per Common Share	\$ (0.00)	\$ (0.01)	\$ (0.01)
	=====	=====	=====
Basic and Diluted Weighted Average Common Shares			
Common Shares Outstanding	91,454,873	73,273,055	91,454,873
	=====	=====	=====

See the accompanying notes to condensed financial statements.

=====

2

ASTRALIS LTD. (A Development Stage Entity) Condensed Statements of Cash Flows (Unaudited)

	Six Months E
	June 30, 2006

Net Cash Used in Operating Activities	(927,831)
Cash Flows from Investing Activities	
Purchases of available-for-sale securities	--
Proceeds from sale of available-for-sale securities	--
Expenditures related to patent	--
Insurance proceeds from fixed asset retirement	--
Purchases of property and equipment	--

Net Cash Used in Investing Activities	--
Cash Flows from Financing Activities	
Proceeds from convertible debenture	350,000
Repurchase of common stock	--
Proceeds from stock subscription receivable	--
Proceeds from exercise of stock options	--

Edgar Filing: ASTRALIS LTD - Form 10QSB

Issuance of common stock, net of offering and transaction costs	--	
Issuance of preferred stock	--	
Private placement offering costs	--	

Net Cash Provided by Financing Activities	350,000	
Net Increase in Cash and Cash Equivalents	(577,831)	
Cash and Cash Equivalents, Beginning of Period	633,468	
Cash and Cash Equivalents, End of Period	\$ 55,637	\$
	=====	=

See the accompanying notes to condensed financial statements.

=====

3

NOTE 1 - BASIS OF PRESENTATION

The unaudited condensed financial statements included herein have been prepared by Astralis, Ltd. ("Astralis"), without audit, pursuant to the rules and regulations of the Securities and Exchange Commission. The financial statements reflect all adjustments that are, in the opinion of management, necessary to fairly present such information. All such adjustments are of a normal recurring nature. Although Astralis believes that the disclosures are adequate to make the information presented not misleading, certain information and footnote disclosures, including a description of significant accounting policies normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America, have been condensed or omitted pursuant to such rules and regulations.

These financial statements should be read in conjunction with the financial statements and the notes thereto included in Astralis' 2005 Annual Report on Form 10-KSB filed with the Securities and Exchange Commission. The results of operations for interim periods are not necessarily indicative of the results for any subsequent quarter or the entire fiscal year ending December 31, 2006. For comparability purposes, certain figures for the prior periods have been reclassified where appropriate to conform with the financial statement presentation used in 2006. These reclassifications had no effect on the reported net loss.

NOTE 2 - DESCRIPTION OF BUSINESS

Astralis is an emerging stage biotechnology company, based in New Jersey and incorporated under the laws of the State of Delaware, which primarily engages in research and development of treatments for immune system disorders and skin diseases. Astralis is currently developing two products. Its primary product, Psoraxine(R), administered by intramuscular injection, is an innovative immunotherapeutic product under development for the treatment of psoriasis. Astralis' second product is for the treatment of arthritis. Astralis is engaged in on-going research of Psoraxine(R), and expects to recommence clinical trials to obtain the approval of the United States Food and Drug Administration for the marketing of Psoraxine(R), and development of the technology underlying the Psoraxine(R), for the treatment of other indications, such as eczema, leishmaniasis and seborrheic dermatitis.

Edgar Filing: ASTRALIS LTD - Form 10QSB

NOTE 3 - GOING CONCERN

Astralis incurred net losses to common stockholders of \$831,012 and \$54,447,528 for the six-month period ended June 30, 2006 and for the period March 12, 2001 (date of inception) to June 30, 2006, respectively. Included in the cumulative net losses was non-cash preferred stock dividend generated from beneficial conversion features of preferred stock in the amount of \$22,218,750.

Pharmaceutical products must undergo an extensive process, including testing in compliance with U.S. Food and Drug Administration ("FDA") regulations, before they can be commercially sold and distributed in the United States. FDA testing occurs in various phases over a multiple number of years. Astralis expects to continue clinical testing of Psoraxine in 2006 and beyond. Astralis will need significant additional funds to complete all of the testing required by the FDA. Currently, Astralis has no products approved for commercial sale and therefore no means to generate revenue.

On March 14, 2005, Astralis issued a press release to disclose the results of its Phase II study for Psoraxine. The Phase II study of its novel immuno-stimulatory product for the treatment of Psoriasis indicated no statistical difference between Astralis' product and a placebo. In the study, Psoraxine was found to be safe and well tolerated.

Based on an analysis of the data from its Phase II study Astralis has developed a hypothesis to explain why the results differed from the long-term improvement of the more than 2,700 patients who were treated with Psoraxine in pre-clinical studies in Venezuela. Astralis intends to reformulate the product and reproduce the clinical studies performed in Venezuela. Astralis hopes to demonstrate an outcome that is more consistent with results from pre-clinical studies.

Astralis raised \$250,000 through a private placement in March of 2006 and an additional \$100,000 in June of 2006. These funds have been completely expended and Astralis does not have sufficient funds to maintain operations. The Board of Directors is considering immediately strategic alternatives for Astralis, including the immediate cessation of operations. Astralis will need to raise significant additional funds from outside sources immediately to maintain its operations and in future periods in order to complete existing and future phases of FDA required testing. Astralis has identified no source of capital and does not know if it will be able to do so.

Consequently, the aforementioned items raise substantial doubt about Astralis' ability to continue as a going concern. Management is seeking to identify additional capital immediately so that it may continue its operations. These funds will be needed in order to finance Astralis' currently anticipated needs for operating and capital expenditures for the remainder of 2006, including the cost to continue clinical trials of Psoraxine(R) and initiate development of pipeline products to treat arthritis and leishmaniasis. Astralis will also need to raise significant additional funds from outside sources in future years in order to complete existing and future phases of FDA required testing.

=====

Astralis' ability to continue as a going concern is dependent upon it raising capital immediately through debt and/or equity financing. There can be no assurance that Astralis will successfully raise the required future financing on terms desirable to Astralis or that the FDA will approve Psoraxine for use in the United States. If Astralis does not obtain the needed funds, it will be required to cease operations. Astralis is actively seeking sources of financing.

Edgar Filing: ASTRALIS LTD - Form 10QSB

Astralis has implemented further dramatic cost reduction measures to extend the availability of its capital and has been operating with minimal resources. The financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets and amounts and classifications of liabilities that might result from the outcome of this uncertainty.

NOTE 4 - STOCK BASED COMPENSATION

Effective January 1, 2006, we adopted the provisions of Statement of Financial Accounting Standards No. 123 (revised 2004), "Share-Based Payment" (SFAS No.123R) requiring that compensation cost relating to share-based payment transactions be recognized under fair value accounting and recorded in the financial statements. The cost is measured at the grant date, based on the calculated fair value of the award, and is recognized as an expense over the employee's requisite service period (generally the vesting period of the equity award). Prior to January 1, 2006, we accounted for share-based compensation to employees in accordance with Accounting Principles Board Opinion No. 25, "Accounting for Stock Issued to Employees" (APB No. 25), and related interpretations. We also followed the disclosure requirements of Statement of Financial Accounting Standards No. 123, "Accounting for Stock-Based Compensation", as amended by Statement of Financial Accounting Standards No. 148, "Accounting for Stock-Based Compensation-Transition and Disclosure". We adopted SFAS No. 123R using the modified prospective method and, accordingly, financial statement amounts for prior periods presented in this Form 10-Q have not been restated to reflect the fair value method of recognizing compensation cost relating to non-qualified stock options.

There was \$36,768 and \$71,876 of compensation cost related to non-qualified stock options recognized in operating results for the three and six months ended June 30, 2006, respectively. Since Astralis has generated losses from its inception, no associated future income tax benefit was recognized for the three or six months ended June 30, 2006.

The fair value of each option award is estimated on the date of grant using the Black-Scholes option-pricing model. Historical volatilities based on the historical stock trading prices of Astralis, Ltd. are used to calculate the expected volatility. We used the simplified method as defined under the SEC Staff Accounting Bulletin No. 107, Topic 14: "Share-based Payment," to derive an expected term. The expected term represents an estimate of the time options are expected to remain outstanding. The risk-free rate for periods within the contractual life of the option is based on the U.S. treasury yield curve in effect at the time of grant. The following table sets forth the assumptions used to determine compensation cost for our stock options consistent with the requirements of SFAS No. 123R:

	Three Months Ended June 30, 2006 -----
Expected volatility	108.00 % - 128.00%
Expected annual dividend yield	0.00%
Risk free rate of return	4.45%
Expected option term (years)	5.00

If Astralis had accounted for share based compensation in accordance with SFAS No. 123R for the six and three months ended June 30, 2005, then \$323,756 and \$154,826 would have been recorded as share based compensation expense, respectively. The following table illustrates the effect on net loss and earnings per share if Astralis had applied the fair value recognition provisions of Statement of Financial Standards No. 123, Accounting for Stock-Based Compensation," to stock-based compensation in the first quarter of 2005.

Edgar Filing: ASTRALIS LTD - Form 10QSB

5

	Three Months Ended June 30, 2005	Six Months Ended June 30, 2005
	(Unaudited)	(Unaudited)
Net loss to common stockholders, as reported	\$ (874,748)	\$ (2,554,945)
Add: Stock-based employee/ director compensation included in reported net loss	--	--
Deduct: Total stock-based employee/director compensation expense under the fair value based method for all awards, net of tax	(154,826)	(323,756)
Pro forma net loss	(1,029,574)	\$ (2,878,701)
Loss per share basic and diluted - as reported	\$ (0.01)	\$ (0.03)
Loss per share basic and diluted - pro forma	\$ (0.01)	\$ (0.04)
Shares used in basic and diluted loss per share amounts	73,273,055	73,248,746

At June 30, 2006, there was \$208,275 of total unrecognized compensation cost related to non-vested non-qualified stock option awards which is expected to be recognized over a weighted-average period of 7.71 years. The total fair value of options vested during the six and three months ended June 30, 2006 was approximately \$29,527 and \$25,174, respectively.

Other than stock options covered by the Stock Incentive Plan, Astralis has no outstanding options to purchase shares of its common stock.

NOTE 5 - CONVERTIBLE NOTES - RELATED PARTY

On June 15, 2006, Astralis issued to Mr. Manuel Tarabay ("Tarabay"), an accredited investor and a current stockholder of Astralis; (i) a convertible promissory note in the principal amount of \$100,000, convertible into shares of Astralis' common stock at \$0.075 per share at any time prior to the redemption date (June 15, 2009), interest will be charged on the note at 6% per annum and (ii) a warrant to purchase 1,333,333 shares of common stock at an exercise price of \$0.1125 per share. The warrants expire five years from the date of issuance.

Astralis may at any time and from time to time, on 45 day's written notice to Tarabay, redeem all or any part of the principal balance of these notes at a price equal to (i) the "Interest Amount," determined pursuant to the note, of the principal amount of the notes to be prepaid, plus (ii) the principal amount of the note to be prepaid. The Interest Amount shall be equal to: (a) if such prepayment occurs on or prior to the first anniversary of the date of the note, six percent (6%) of the principal amount thereof; (b) if such prepayment occurs after the first anniversary date and prior to the second anniversary date, twelve percent (12%) of the aggregate principal amount thereof; and (c) if such

Edgar Filing: ASTRALIS LTD - Form 10QSB

prepayment occurs after the second anniversary date, eighteen percent (18%) of the aggregate principal price thereof.

On March 31, 2006, Astralis issued to Blue Cedar Limited ("Blue Cedar"), an accredited investor and a current stockholder of Astralis; (i) a convertible promissory note in the principal amount of \$250,000, convertible into shares of Astralis' common stock at \$0.09 per share at any time prior to the redemption date (March 31, 2009), interest will be charged on the note at 6% per annum and (ii) a warrant to purchase 2,777,778 shares of common stock at an exercise price of \$0.135 per share. The warrants expire five years from the date of issuance.

Astralis may at any time and from time to time, on 45 day's written notice to Blue Cedar, redeem all or any part of the principal balance of these notes at a price equal to (i) the "Interest Amount," determined pursuant to the note, of the principal amount of the notes to be prepaid, plus (ii) the principal amount of the note to be prepaid. The Interest Amount shall be equal to: (a) if such prepayment occurs on or prior to the first anniversary of the date of the note, six percent (6%) of the principal amount thereof; (b) if such prepayment occurs after the first anniversary date and prior to the second anniversary date, twelve percent (12%) of the aggregate principal amount thereof; and (c) if such prepayment occurs after the second anniversary date, eighteen percent (18%) of the aggregate principal price thereof.

=====

6

Pursuant to EITF 98-5 "Accounting for Convertible Securities with Beneficial Conversion Features or Contingently Adjustable Conversion Ratios" and EITF 00-27 "Application of Issue No. 98-5 to Certain Convertible Instruments", Astralis has recorded a discount to the convertible notes in the amount of \$350,000 based on the relative fair value of the debt and warrants in addition to the beneficial conversion feature (the conversion price into common shares being less than the market price of common shares on the date the loan was issued). The discount will be amortized as interest expense over the life of the note.

For a period ending four years from the date of issuance, Blue Cedar and Tarabay shall have the right to cause Astralis to register the shares of Common Stock issuable upon conversion or exercise of the notes or warrants under the Act, as amended, at Astralis' expense (exclusive of underwriting discounts and commissions and fees of counsel to such Subscribers), subject to certain restrictions.

Also during the same period set forth above, Blue Cedar and Tarabay shall have the right, to participate on a "piggyback basis" in a registration by Astralis under the Act, subject to certain restrictions, including underwriter hold-backs.

Astralis evaluated its convertible debt instruments for possible application of derivative accounting under Statement of Financial Accounting Standard ("SFAS") No 133: Accounting for Derivative Instruments and Hedging Activities, Emerging Issues Task Force ("EITF") 00-19: Accounting for Derivative Financial Instrument Indexed to, and Potentially Settled in, a Company's Own Stock, EITF 01-6: The Meaning of "Indexed to a Company's Own Stock" and EITF 05-2: The Meaning of "Conventional Convertible Debt Instrument" in Issue No. 00-19. Astralis determined its convertible debt was deemed "conventional" and therefore not subject to derivative accounting.

NOTE 6 - CAPITAL STOCK ACTIVITY

Edgar Filing: ASTRALIS LTD - Form 10QSB

On January 27, 2006, Astralis issued options to purchase 182,000 shares of common stock to a former Chief Executive Officer ("CEO"). The options were issued with an exercise price equal to the market price on the date of issuance (\$0.03 on January 27, 2006) and with a term of 5 years and vested immediately. Additionally, on January 27, 2007 an additional 182,000 options will become vested exercisable at the market price on that date for a term of 5 years. The options were issued pursuant to a Separation Agreement and General Release, by and between Astralis and former CEO, which was signed on January 25, 2006.

NOTE 7 - NET LOSS PER SHARE

Basic and diluted net loss per common share are presented in accordance with Statement of Financial Accounting Standards No. 128, Earnings Per Share ("FAS 128"), for all periods presented. In accordance with FAS 128, basic and diluted net loss per common share have been computed using the weighted-average number of shares of common stock outstanding during the period. Shares associated with stock options, stock warrants, and convertible debt are not included because the inclusion would be anti-dilutive (i.e., reduce the net loss per share). The total numbers of such shares excluded from diluted net loss per common share were 55,102,355 and 16,847,891 at June 30, 2006 and 2005, respectively.

=====

7

NOTE 8 - SUPPLEMENTARY DISCLOSURE OF CASH FLOW INFORMATION

In March and April of 2006, Astralis financed \$92,079 of certain insurance premiums by entering into a short-term note payable. The notes mature within one year and have interest rates between 7.75% and 8.75% per annum. As of June 30, 2006, these note had an outstanding balance of \$47,625.

NOTE 9 - SUBSEQUENT EVENTS

On July 16, 2006, Astralis received the resignation of Michael Ashton, a member of the Board of Directors of Astralis. Mr. Ashton's resignation was effective as of July 16, 2006. Since June 30, 2006 until the filing date of this report Astralis has raised an additional \$44,980 through the issuance of convertible debentures.

=====

8

SPECIAL CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This filing contains many forward-looking statements that involve substantial risks and uncertainties. You can identify these statements by forward-looking words such as "may," "will," "expect," "anticipate," "believe," "estimate" and "continue" or similar words. You should read statements that contain these words carefully because they discuss our future expectations, contain projections of our future operating results or of our financial condition or state other "forward-looking" information.

We believe that it is important to communicate our future expectations to our investors. However, we may be unable to accurately predict or control events in the future. The factors listed in the section captioned "Risk Factors," as well as any other cautionary language in this filing, provide examples of risks,

Edgar Filing: ASTRALIS LTD - Form 10QSB

uncertainties and events that may cause our actual results to differ materially from the expectations we describe in our forward-looking statements. Before you invest in our common stock, you should be aware that the occurrence of certain of the events described in the Risk Factors section could seriously harm our business.

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OR PLAN OF OPERATION

The following discussion of our financial condition and plan of operation should be read in conjunction with our financial statements and the related notes included elsewhere in this quarterly report on Form 10-QSB. This quarterly report contains certain statements of a forward-looking nature relating to future events or our future financial performance. We caution prospective investors that such statements involve risks and uncertainties, and that actual events or results may differ materially. In evaluating such statements, prospective investors should specifically consider the various factors identified in this quarterly report, including the matters set forth under the caption "Risk Factors" which could cause actual results to differ materially from those indicated by such forward-looking statements. We disclaim any obligation to update information contained in any forward-looking statement.

Overview

General

We are a development stage biotechnology company engaged primarily in the research and development of treatments for immune system disorders and skin diseases, such as psoriasis and psoriatic and rheumatoid arthritis. Our initial product candidate, Psoraxine(R), is a protein extract used for the treatment of the skin disease psoriasis.

Currently, if we can identify additional sources of capital, we will engage in the following activities to further our development efforts of our initial product candidate:

- o Ongoing research and development of Psoraxine(R);
- o Recommencing clinical trials to obtain the approval of the United States Food and Drug Administration for the marketing of Psoraxine(R); and
- o Developing technology underlying Psoraxine(R) for the treatment of indications other than psoriasis, such as arthritis, eczema, seborrheic dermatitis and leishmaniasis.

Astralis was originally incorporated under the laws of the State of Colorado in 1999 under the name Hercules Development Group, Inc. We subsequently changed our name to Astralis Pharmaceuticals Ltd. and, in November 2001, reincorporated under the laws of the State of Delaware under our present name. Our main office is located at 75 Passaic Avenue, Fairfield, New Jersey 07004.

As of the date of this filing, Astralis' liabilities exceed its cash. Because of its lack of capital, it is engaged in virtually no activities with respect to any research and development. If Astralis does not acquire additional cash within days, it will be forced to cease operations.

Recent Developments

August 2006 Private Placement

Astralis is currently engaged in a private placement whereby it has received proceeds of \$44,980 as of August 21, 2006. The private placement is

Edgar Filing: ASTRALIS LTD - Form 10QSB

expected to be completed by August 31, 2006. In connection with this private placement, Astralis has issued to Lipworth Capital and SkyePharma, PLC, each an accredited investor and current stockholder of Astralis, (i) convertible

=====

9

promissory notes in the principal amount in aggregate of \$44,980, convertible into shares of Astralis' common stock at \$0.075 per share at any time prior to the redemption date (August 21, 2009), interest will be charged on the note at 6% per annum and (ii) warrants to purchase 1,933,066 shares of common stock at an exercise price of \$0.1125 per share. The warrants expire five years from the date of issuance. The securities offered and sold in this private placement were sold in reliance on an exemption from the registration requirements under Regulation D of the Securities Act.

No assurance can be given that any additional funds will be invested by any parties. If Astralis does not receive any addition funds immediately it will be required to cease operations. If it ceases operations, shares of common stock of Astralis will be virtually without value.

Departure of Directors and Principal Officer

On July 16, 2006, Michael Ashton, a member of the Board of Directors of Astralis and one of SkyePharma's two representatitves on the Board, announced his resignation from the Board, effective July 17, 2005. Mr. Ashton recently retired from the Board of SkyePharma, PLC and consequently resigned from the Board of Astralis, LTD. Mr. Ashton's announcement did not reference a disagreement with Astralis on any matter relating to Astralis' operations.

Proposed Amendment to the Certificate of Incorporation

The Board of Directors has approved an amendment to the Certificate of Incorporation of Astralis, pursuant to which Astralis will be authorized to issue an additional 200,000,000 shares of Common Stock. The Amendment will be subject to the approval of the stockholders of Astralis to be sought at a Special Meeting to be held during the third quarter of 2006.

Plan of Operation

Three months ended June 30, 2006 compared to three months ended June 30, 2005.

For the three months ended June 30, 2006:

For the three months ended June 30, 2006, we had no revenue from operations and incurred operating expenses of \$405,217 which consisted primarily of:

- o Research and development costs of \$125,723 including evaluation of clinical trial results, reformulation of Psoraxine(R) and activity testing in animals.
- o General and administrative costs of \$238,845, including professional fees, rent, salaries for management and our general corporate expenditures.

As a result, during the three months ended June 30, 2006, we incurred a net loss of \$403,769.

Edgar Filing: ASTRALIS LTD - Form 10QSB

For the three months ended June 30, 2005:

For the three months ended June 30, 2005, we had no revenue from operations and incurred operating expenses of \$879,720 which consisted primarily of:

- o Research and development costs of \$507,708, including evaluation of clinical trial results, reformation of Psoraxine(R) and activity testing in animals. Research and development costs did not include any allocation of costs related to the formulation and development of Psoraxine(R) under our Services Agreement with SkyePharma PLC, dated December 10, 2001, due to the expiration of the Services Agreement in December 2004.
- o General and administrative costs of approximately \$365,288, including professional fees, rents, salaries for management and our general corporate expenditures.
- o As a result, during the three months ended June 30, 2005, we incurred a net loss of \$874,758.

Comparison

Our research and development expenses declined from \$507,708 during the three months ended June 30, 2005 to \$125,723 during the three months ended June 30, 2006, primarily due to the completion of the clinical trial of Psoraxine(R) during the first quarter of 2005.

=====

10

By comparison to the three months ended June 30, 2005, our general and administrative costs for the three months ended June 30, 2006 decreased by \$126,443 primarily due to management's cost control initiatives and downsizing.

Losses of \$403,769 for the three months ended June 30, 2006 were \$470,979 less than losses for the three months ended June 30, 2005, reflecting the completion of the Psoraxine(R) clinical trial and management's cost control initiatives implemented during 2006.

Six months ended June 30, 2006 compared to six months ended June 30, 2005.

For the six months ended June 30, 2006:

For the six months ended June 30, 2006, we had no revenue from operations and incurred operating expenses of \$835,359 which consisted primarily of:

- o Research and development costs of \$289,750 including evaluation of clinical trial results, reformulation of Psoraxine(R) and activity testing in animals.
- o General and administrative costs of \$466,755, including professional fees, rent, salaries for management and our general corporate expenditures.

As a result, during the six months ended June 30, 2006, we incurred a net loss of \$831,012.

For the six months ended June 30, 2005:

Edgar Filing: ASTRALIS LTD - Form 10QSB

For the six months ended June 30, 2005, we had no revenue from operations and incurred operating expenses of \$2,570,815 which consisted primarily of:

- o Research and development costs of \$1,594,372, including evaluation of clinical trial results, reformation of Psoraxine(R) and activity testing in animals. Research and development costs did not include any allocation of costs related to the formulation and development of Psoraxine(R) under our Services Agreement with SkyePharma PLC, dated December 10, 2001, due to the expiration of the Services Agreement in December 2004.
- o General and administrative costs of approximately \$961,797, including professional fees, rents, salaries for management and our general corporate expenditures.
- o As a result, during the six months ended June 30, 2005, we incurred a net loss of \$2,554,945.

Comparison

Our research and development expenses declined from \$1,594,372 during the six months ended June 30, 2005 to \$289,750 during the six months ended June 30, 2006, primarily due to the completion of the clinical trial of Psoraxine(R) during the first quarter of 2005.

By comparison to the six months ended June 30, 2005, our general and administrative costs for the six months ended June 30, 2006 decreased by \$495,042 primarily due to management's cost control initiatives and downsizing.

Losses of \$831,012 for the six months ended June 30, 2006 were \$1,723,933 less than losses for the six months ended June 30, 2005, reflecting the completion of the Psoraxine(R) clinical trial and management's cost control initiatives implemented during 2006.

The Next Twelve Months

At June 30, 2006 we had cash balances of \$55,637, and accounts payable of \$273,486. As of the date of this filing Astralis' liabilities exceed its cash. If Astralis does not acquire additional cash within days it will be forced to cease operations. If Astralis identifies significant capital, which does not seem likely, it would continue to operate as follows:

- o Our primary focus would be to further development efforts of our initial product candidate, Psoraxine(R). In March 2005, Astralis announced that the Phase II study of its novel immuno-stimulatory product for the treatment of Psoriasis did not meet the primary study endpoint upon completion of the treatment phase of the study. In the study, Psoraxine(R) was found to be safe and well-tolerated. Accordingly,

=====

we analyzed the data and developed a hypothesis that may explain why we received these unexpected results. In this regard, we have implemented dramatic cost containment measures; realigning development activities to focus on such things as formulation, manufacturing, analytical protocols and potency; and we tested the hypothesis to explain unexpected results and determine the best

Edgar Filing: ASTRALIS LTD - Form 10QSB

course for future development.

- o We would to implement our business plan and facilitate the operations of our company. The business plan would be implemented in phases: during the first phase we expect to test the hypothesis developed recently to assess causes for unexpected results in the Phase II trial. During the second phase, test results will be used to design and begin a new Phase II trial. We expect that we would be required to incur expenses of approximately \$2,250,000 to third parties in connection with continuing development of Psoraxine(R).
- o We would spend approximately \$550,000 to pay management salaries and salaries of employees, a portion of which is treated as research and development expense.
- o We would expend approximately \$700,000 for our general administrative and working capital requirements.
- o In connection with last year's August 2005 private placement of securities to Blue Cedar, because a registration statement covering the resale of the Blue Cedar shares was not filed or effective by December 31, 2005, we are required to pay liquidated damages payments of \$10,000 per month, being 0.5% of the aggregate purchase price plus 10% annum interest until such time as a registration statement covering the resale of securities sold to Blue Cedar is declared effective by the Securities and Exchange Commission.
- o We will need to raise additional funds immediately to continue our operations for the period following the second quarter of 2006 and to fund any of the activities described above. Furthermore, substantial additional funds will be needed in order to fund our continued efforts to obtain FDA approval of Psoraxine(R). No assurance can be given that we will be able to obtain financing on terms that we find acceptable, or that they will enable us to satisfy our cash requirements. In addition, raising additional funds by selling additional shares of our capital stock will dilute the ownership interest of our stockholders. Presently, neither our management nor our bankers have identified new sources of capital. If we do not obtain additional funds, we will likely be required to cease operations.

If Astralis is unable to identify several million dollars, although it will not cease operations, it will be unable to pursue any significant drug development activities.

ITEM 3. CONTROLS AND PROCEDURES

(a) Evaluation of disclosure controls and procedures.

Based on their evaluation as of the end of the period covered by this Quarterly Report on Form 10-QSB, our Interim Chief Executive Officer and Chief Financial Officer has concluded that our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934 (the "Exchange Act")) are effective to ensure that information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission's rules and forms.

(b) Changes in internal controls.

There were no significant changes in our internal controls or in other factors that could significantly affect these controls subsequent to the date of

Edgar Filing: ASTRALIS LTD - Form 10QSB

their evaluation, including any corrective actions with regard to significant deficiencies and material weaknesses.

RISK FACTORS

You should carefully consider each of the following risk factors and all of the other information in this report. The following risks relate principally to Astralis' business. If any of the following risks actually occur, the business, financial condition or results of operations of Astralis could be materially adversely affected. As a result, the market price of shares of Astralis' common stock could decline significantly

=====

12

We are insolvent; we will need to obtain additional funds immediately to support our operating expenses.

As of August 18, 2006, we have \$9,390 in available cash and accounts payable of approximately \$293,486. Based on our current plans, we believe that we do not have sufficient funds to meet our operating expenses and capital requirements beyond the date of this filing. We will need to raise additional funds immediately to continue our operations. Furthermore, substantial additional funds will be needed in order to fund our continued efforts to obtain FDA approval of Psoraxine(R), especially given the failure of our Phase II study to meet its primary endpoint. No assurance can be given that we will be able to obtain financing, or successfully sell assets or stock, or, even if such transactions are possible, that they will be on terms reasonable to us or that they will enable us to satisfy our cash requirements. In addition, raising additional funds by selling additional shares of our capital stock will dilute the ownership interest of our stockholders. If we do not obtain additional funds immediately we will have to cease operations. We are actively seeking sources of financing. If Astralis ceases operations, its shares of common stock will have virtually no value.

As a result of our losses and the matters described in the preceding paragraph, the Independent Auditors' Report on our financial statements includes a paragraph indicating doubt about our ability to continue as a going concern. The financial statements that accompany this report do not include any adjustments that might be necessary if we are unable to continue as a going concern.

We have no sales; we will not have sales in the foreseeable future; we are in an early stage of development and we may never sell products or become profitable.

We commenced our current operations in 2001 and such operations remain in an early stage of development. We have no products approved for sale and therefore, no means to generate revenue. We have not commercialized any products, had no revenues and had incurred a cumulative net loss of \$54,447,528 as of June 30, 2006 which has increased to date. The cumulative net loss through June 30, 2006 includes non-cash preferred stock dividends of \$22,218,750. We expect that substantial losses will continue for the foreseeable future. In order to obtain revenue from the sales of our product candidate, Psoraxine(R), we must successfully develop, test, obtain regulatory approval for, manufacture, market and eventually sell such product candidate. Our expenses have consisted principally of costs incurred in research and development and from general and administrative costs associated with our operations. We expect our expenses to increase and to continue to incur operating losses for the next several years as

Edgar Filing: ASTRALIS LTD - Form 10QSB

we continue our research and development efforts for Psoraxine(R) and any subsequent product candidates. Commercialization of any of our products will take a significant amount of time and successful commercialization may not occur at all. As a result, we may never become profitable.

Psoraxine(R) may never be approved by the FDA because the results of our Phase II study failed to meet its primary study endpoint.

We have focused our development efforts to date on conducting clinical trials for an immuno-stimulatory drug, Psoraxine(R), for the treatment of psoriasis. We recently conducted a randomized, double-blinded, placebo-controlled clinical study involving 120 patients with moderate to severe psoriasis who received six (6) intramuscular injections of Psoraxine(R). The primary endpoint of the study was a specified level of improvement of symptoms measured in accordance with the Psoriasis Area and Severity Index, or PASI, which is a measurement scale that ranks the severity of symptoms of patients suffering from psoriasis. Our initial analysis of the preliminary data showed no statistically significant improvement of those Phase II study patients who received six injections of Psoraxine(R) for a twelve weeks treatment period compared to patients taking a placebo.

The failure of our Phase II study to meet its primary endpoint makes FDA approval of Psoraxine(R) substantially more uncertain. To continue Psoraxine(R)'s development and to obtain FDA approval to market Psoraxine(R), we must analyze the data from the Phase II study to identify why the Phase II study failed to meet its primary endpoint. We must then undertake additional Phase I or Phase II clinical trials that are adjusted to account for the cause or causes of the initial Phase II study's failure. Although we have already identified a number of possible reasons for the failure to demonstrate efficacy in the recent Phase II trial, and we have also developed a preliminary plan for new clinical studies, there can be no guarantee that we will be able to identify with certainty why our Phase II study failed to meet its primary endpoint and that we will be able to make the needed adjustments for further Phase II studies to be successful. There is also no guarantee that the FDA would approve Psoraxine(R) even if we deem additional clinical trials to be successful.

We have devoted most of our resources to the development of Psoraxine(R) and our business is dependent on its success. In the United States, the marketing of Psoraxine(R) depends on FDA approval of the product. Analyzing the

=====

Phase II study data and conducting additional Phase II clinical trials will delay FDA approval. We may also decide to discontinue further clinical trials of Psoraxine(R), which would prevent us from obtaining FDA approval. If we are not able to obtain FDA approval for Psoraxine(R), we would be unable to sell the product.

Recent and future changes in senior management and board composition may affect our ability to implement our business plan. In addition we only have one member of our Audit Committee.

On January 25, 2006, we accepted the resignation James Sharpe, effective as of December 31, 2005 with respect to his position as Chief Executive Officer, President and member of the Board of Directors. Michael Garone, our Chief Financial Officer, currently serves as the interim Chief Executive Officer and interim President. Mr. Sharpe is our third Chief Executive Officer and President to resign in an 18 month period. Our ability to implement our business strategy

Edgar Filing: ASTRALIS LTD - Form 10QSB

may be adversely affected if we continue to experience unplanned senior management changes in the future or if we are unable to successfully integrate our current and future senior management personnel into our organization. Additionally there have been changes to the composition of our Board of Directors. On July 16, 2006, Astralis received the resignation of Michael Ashton as a member of the Board of Directors. Mr. Ashton's resignation was effective as of July 17, 2006. Additionally, on May 5, 2006, Astralis received the resignation of Fabien Pictet as a member of the Board of Directors. Mr. Pictet's resignation was effective as of May 4, 2006. Further, in December 2005, Steven Fulda resigned as a member of the Audit Committee and member of the Board of Directors. As a result of Mr. Fulda's resignation, we only have one member of the Audit Committee. Moreover, our Audit Committee does not contain a member that qualifies as a financial "expert" as defined by Item 401(e) of Regulation S-B of the Exchange Act.

One of our existing stockholders can exert control over us and may not make decisions that further the best interests of all stockholders.

SkyePharma owns approximately 39.7% of our outstanding common stock. As a result, SkyePharma may exert a significant degree of influence over our management and affairs and over matters requiring stockholder approval, including the election of directors and approval of significant corporate transactions. Furthermore, the interests of SkyePharma may not always coincide with our interests or the interests of other stockholders and accordingly, they could cause us to enter into transactions or agreements which we would not otherwise consider. In addition, this concentration of ownership may delay or prevent a merger or acquisition resulting in a change in our control might affect the market price of our common stock, even when such a change in control may be in the best interest of all stockholders.

We may not be successful in the development and commercialization of products.

We may not develop products that prove to be safe and effective, that meet applicable regulatory standards or that we can manufacture at reasonable costs or market successfully. Successful products will require significant development and investment, including testing, to demonstrate their safety and efficacy prior to their commercialization. We have not proven our ability to develop and commercialize products. We must conduct a substantial amount of additional research and development before any regulatory authority will approve our initial product candidate, Psoraxine(R). Our research and development and clinical trials may not confirm the safety and efficacy of our products, in which case regulatory authorities may not approve them. In addition, even if we successfully complete our research and development efforts, Psoraxine(R) may not perform in the manner we anticipate, and may not be accepted for use by the public.

Substantial additional funds and effort will be necessary for further development and commercialization of Psoraxine(R).

Our initial product candidate, Psoraxine(R), will require the commitment of substantial resources to move it towards commercialization. Before obtaining regulatory approvals for the commercial sale of Psoraxine(R), we must demonstrate the safety and efficacy of our product candidate through preclinical testing and clinical trials. Conducting clinical trials involves a lengthy, expensive and uncertain process. Completion of clinical trials may take several years or more. The length of time generally varies substantially according to the type, complexity, novelty and intended use of the product. If we or the U.S. Food and Drug Administration believe that our clinical trials expose participating patients to unacceptable health risks, we may suspend such trials. We may encounter problems in our studies which will cause us or the FDA to delay or suspend the studies. Some of the factors that may delay our commencement and

Edgar Filing: ASTRALIS LTD - Form 10QSB

rate of completion of clinical trials include:

- o ineffectiveness of the study compound, or perceptions by physicians that the compound will not successfully treat a particular indication;
- o inability to manufacture sufficient quantities of compounds for use in clinical trials;
- o failure of the FDA to approve our clinical trial protocols;

=====

14

- o slower than expected rate of patient recruitment;
- o unforeseen safety issues; or
- o government or regulatory delays.

The failure of future clinical trials may harm our business, financial condition and results of operations.

Our potential therapeutic products face a lengthy and uncertain regulatory process. If we do not obtain regulatory approval of our potential products, we will not be able to commercialize these products.

The FDA must approve any therapeutic product before it can be marketed in the United States. Before we obtain FDA approval of a new drug application or biologics license application, the product must undergo extensive testing, including animal and human clinical trials, which can take many years and requires substantial expenditure. Data obtained from such testing may be susceptible to varying interpretations, which could delay, limit or prevent regulatory approval. In addition, changes in regulatory policy for product approval during the period of product development and regulatory agency review of each submitted new drug application may cause delays or rejections. We must devote a substantial amount of time and resources in the regulatory process in order to obtain regulatory approval of our initial product candidate, Psoraxine(R).

Because our initial product candidate, Psoraxine(R), involves the application of new technologies and may be used upon new therapeutic approaches, government regulatory authorities may subject this product to more rigorous review and may grant regulatory approvals more slowly for this product than for products using more conventional technologies. We have not received approval from the FDA to market or commercialize Psoraxine(R). The regulatory agencies of foreign governments must also approve any therapeutic product we may develop before the product can be sold in those countries. To date, although we have obtained regulatory approval for clinical testing of Psoraxine(R) in Venezuela, we have not sought, nor have we obtained, regulatory approval for the commercialization of Psoraxine(R) in Venezuela because, among other things, we do not have manufacturing facilities in that country and such facilities are required by regulatory authorities in Venezuela before granting commercial approval for a proposed drug.

Even after investing significant time and resources, we may not obtain regulatory approval for our product. If we do not receive regulatory approval, we cannot sell the product. Even if we receive regulatory approval, this approval may place limitations on the indicated uses for which we can market the

Edgar Filing: ASTRALIS LTD - Form 10QSB

product. Further, after granting regulatory approval, regulatory authorities subject a marketed product and its manufacturer to continual review, and discovery of previously unknown problems with a product or manufacturer may result in restrictions on the product, manufacturer and manufacturing facility, including withdrawal of the product from the market. In certain countries, regulatory agencies also set or approve prices.

Even if product candidates emerge successfully from clinical trials, we may not be able to successfully manufacture, market and sell them.

We have not successfully completed clinical trials of Psoraxine(R). If Psoraxine(R) emerges successfully from clinical trials and obtains regulatory approval, we will either commercialize products resulting from our proprietary programs directly or through licensing arrangements with other companies. We have no experience in manufacturing and marketing, and we currently do not have the resources or capability to manufacture, market or sell our products on a commercial scale. In order to commercialize Psoraxine(R) directly, we would need to develop or obtain through outsourcing arrangements the capability to manufacture, market and sell products. In addition, we currently do not have any agreements for the marketing or sale of any of our products and we may not be able to enter into such agreements on commercially reasonable terms, or at all.

We license and do not own our intellectual property. Any inability to protect our proprietary technologies adequately could harm our competitive position.

We license, and do not own, the intellectual property rights to Psoraxine(R). Dr. Jose Antonio O'Daly is the owner of the patent for Psoraxine(R). Under the terms of a license agreement and assignment of license agreement, we have the right to use any patent issued pursuant to Dr. O'Daly's patent application. We also have rights to other patents filed by Dr. O'Daly under the terms of our employment agreement with him. Our success will depend in part on our ability to obtain patents and maintain adequate protection of other intellectual property for our technologies and products in the United States and other countries. If we do not adequately protect our intellectual property, competitors may be able to use our technologies and erode or negate our competitive advantage. The laws of some foreign countries do not protect our proprietary rights to the same extent as the laws of the United States, and we may encounter significant problems in protecting our proprietary rights in these foreign countries.

The patent positions of biotechnology companies, including our patent positions, involve complex legal and factual questions and, therefore, validity and enforceability cannot be predicted with certainty. Patents may be

=====

challenged, deemed unenforceable, invalidated or circumvented. We will be able to protect our proprietary rights from unauthorized use by third parties only to the extent that we cover our proprietary technologies with valid and enforceable patents or we effectively maintain such proprietary technologies as trade secrets. We will apply for patents covering both our technologies and product candidates as we deem appropriate. However, we may fail to apply for patents on important technologies or products in a timely fashion, or at all, and in any event, the applications we do file may be challenged and may not result in issued patents. Any future patents we obtain may not be sufficiently broad to prevent others from practicing our technologies or from developing competing products. Furthermore, others may independently develop similar or alternative

Edgar Filing: ASTRALIS LTD - Form 10QSB

technologies or design around our patented technologies. In addition, others may challenge or invalidate our patents, or our patents may fail to provide us with any competitive advantages. If we encounter challenges to the use or validity of any of our patents, resulting in litigation or administrative proceedings, we would incur substantial costs and the diversion of management in defending the patent. In addition, we do not control the patent prosecution of technology that we license from others. Accordingly, we cannot exercise the same degree of control over this intellectual property as we would over technology we own.

We rely upon trade secrets protection for our confidential and proprietary information. We have taken measures to protect our proprietary information. These measures may not provide adequate protection for our trade secrets or other proprietary information. We seek to protect our proprietary information by entering into confidentiality agreements with employees, collaborators and consultants. Nevertheless, employees, collaborators or consultants may still disclose our proprietary information, and we may not be able to meaningfully protect our trade secrets. In addition, others may independently develop substantially equivalent proprietary information or techniques or otherwise gain access to our trade secrets.

Many potential competitors, which have greater resources and experience than we do, may develop products and technologies that could make ours obsolete.

Companies in the biotechnology industry face rapid technological change in a rapidly evolving field. Our future success will depend on our ability to maintain a competitive position with respect to technological advances. Rapid technological development by others may result in our products and technologies becoming obsolete.

We face, and will continue to face, intense competition from organizations such as large biotechnology and pharmaceutical companies, as well as academic and research institutions and government agencies. Our competitors may include Biogen, Genentech/Xoma, Amgen, Wyeth, Abbott Laboratories and Novartis. These organizations may develop technologies that provide superior alternatives to our technologies. Further, our competitors may be more effective at implementing their technologies to develop commercial products.

Any products that we develop through our technologies will compete in multiple, highly competitive markets. Many of the organizations competing with us in the markets for such products have greater capital resources, research and development and marketing staffs, facilities and capabilities, and greater experience in obtaining regulatory approvals, product manufacturing and marketing. Accordingly, our competitors may be able to develop technologies and products more easily, which would render our technologies and products obsolete and noncompetitive.

If we lose our key personnel or fail to attract and retain additional personnel, we may be unable to discover and develop our products.

We depend on the services of Dr. Jose Antonio O'Daly, the Chairman of our Board of Directors and our Chief Scientific Officer, and Michael Garone, interim Chief Executive Officer, interim President and Chief Financial Officer, the loss of whose services would adversely impact the achievement of our objectives. To execute our business plan fully it is essential that we retain these executives. In addition, recruiting and retaining qualified scientific personnel to perform future research and development work will be critical to our success. Although we believe we can successfully attract and retain qualified personnel, we face intense competition for experienced scientists. Failure to attract and retain skilled personnel would prevent us from pursuing collaborations and developing our products and core technologies to the extent otherwise possible.

Our planned activities will require additional expertise. These activities

Edgar Filing: ASTRALIS LTD - Form 10QSB

will require the addition of new personnel, including management, and the development of additional expertise by existing management personnel. The inability to acquire or develop this expertise could impair the growth, if any, of our business.

If we face claims in clinical trials of a drug candidate, these claims will divert our management's time and we will incur litigation costs.

We face an inherent business risk of clinical trial liability claims in the event that the use or misuse of Psoraxine(R) results in personal injury or death. We may experience clinical trial liability claims if our drug candidates are misused or cause harm before regulatory authorities approve them for marketing. Although we currently maintain clinical liability insurance coverage, it may not sufficiently cover any claims made against us and may not be available in the future on acceptable terms, if at all. Any claims against us,

=====

16

regardless of their merit, could strain our financial resources in addition to consuming the time and attention of our management. Law suits for any injuries caused by our products may result in liabilities that exceed our total assets.

Some of our existing stockholders can exert control over us and many not make decisions that further the best interests of all stockholders.

Our officers, directors and principal stockholders (greater than 5% stockholders) together control approximately 78% of our outstanding common stock. As a result, these stockholders, if they act individually or together, may exert a significant degree of influence over our management and affairs and over matters requiring stockholder approval, including the election of directors and approval of significant corporate transactions. Furthermore, the interests of this concentration of ownership may not always coincide with our interests or the interests of other stockholders and accordingly, they could cause us to enter into transactions or agreements which we would not otherwise consider. In addition, this concentration of ownership may delay or prevent a merger or acquisition resulting in a change in control of us and might affect the market price of our common stock, even when such a change in control may be in the best interest of all stockholders.

The market price of our common stock may be highly volatile.

The market price of our common stock has been and will likely continue to be highly volatile. From the date trading of our common stock commenced until August 15, 2006, the range of our stock price has been between \$0.02 and \$7.15. Factors including announcements of technological innovations by us or other companies, regulatory matters, new or existing products or procedures, concerns about our financial position, operating results, government regulation, or developments or disputes relating to agreements, patents or proprietary rights may have a significant impact on the market price of our stock. In addition, potential dilutive effects of future sales of shares of common stock by us, our stockholders, or the holders of warrants and options, could have an adverse effect on the price of our common stock.

A large number of shares of our common stock may be sold in the market, which may depress the market price of our common stock.

Sales of substantial amounts of our common stock in the public market, or the perception that these sales might occur, could materially and adversely affect

Edgar Filing: ASTRALIS LTD - Form 10QSB

the market price of our common stock or our future ability to raise capital through an offering of our equity securities. We have an aggregate of 91,454,873 shares of our common stock outstanding. If all options and warrants currently outstanding to purchase shares of our common stock are exercised, there will be approximately 150,105,362 shares of common stock outstanding. Of the outstanding shares, up to 73,172,055 shares are freely tradable without restriction or further registration under the Securities Act, unless the shares are held by one of our "affiliates" as such term is defined in Rule 144 of the Securities Act. The remaining shares may be sold only pursuant to a registration statement under the Securities Act or an exemption from the registration requirements of the Securities Act. The sale and distribution of these shares may cause a decline in the market price of our common stock. In addition we will be obligated to file a registration statement within approximately 30 days of the final closing of our private placement covering the resale of all shares included therein, as well as the shares underlying the warrants. Certain existing stockholders have the right to include their securities in such registration statement.

Our common stock qualifies as a "penny stock" under SEC rules which may make it more difficult for our stockholders to resell their shares of our common stock.

Our common stock trades on the OTC Bulletin Board. As a result, the holders of our common stock may find it more difficult to obtain accurate quotations concerning the market value of the stock. Stockholders also may experience greater difficulties in attempting to sell the stock than if it were listed on a stock exchange or quoted on the Nasdaq National Market or the Nasdaq Small-Cap Market. Because our common stock does not trade on a stock exchange or on the Nasdaq National Market or the Nasdaq Small-Cap Market, and the market price of the common stock is less than \$5.00 per share, the common stock qualifies as a "penny stock." SEC Rule 15c-9 under the Securities Exchange Act of 1934 imposes additional sales practice requirements on broker-dealers that recommend the purchase or sale of penny stocks to persons other than those who qualify as an "established customer" or one "accredited investor." This includes the requirement that a broker-dealer must make a determination on the appropriateness of investments in penny stocks for the customer and must make special disclosures to the customer concerning the risks of penny stocks. Application of the penny stock rules to our common stock could adversely affect the market liquidity of the shares, which in turn may affect the ability of holders of our common stock to resell the stock.

=====

PART II. OTHER INFORMATION

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

On June 15, 2006, Astralis issued to Mr. Manuel Tarabay, an accredited investor and a current stockholder of Astralis; (i) a convertible promissory note in the principal amount of \$100,000, convertible into shares of Astralis' common stock at \$0.075 per share at any time prior to the redemption date (June 15, 2009), interest will be charged on the note at 6% per annum and (ii) a warrant to purchase 1,333,333 shares of common stock at an exercise price of \$0.1125 per share. The warrants expire five years from the date of issuance. Astralis received proceeds of 100,000 in connection with this private placement. The securities offered and sold in this private placement were sold in reliance on an exemption from the registration requirements under Regulation D of the Securities Act.

Edgar Filing: ASTRALIS LTD - Form 10QSB

Astralis is currently engaged in a private placement whereby it has received proceeds of \$44,980 as of August 21, 2006. The private placement is expected to be completed by August 31, 2006. In connection with this private placement, Astralis has issued to Lipworth Capital and SkyePharma, PLC, each an accredited investor and current stockholder of Astralis, (i) convertible promissory notes in the principal amount in aggregate of \$44,980, convertible into shares of Astralis' common stock at \$0.075 per share at any time prior to the redemption date (August 21, 2009), interest will be charged on the note at 6% per annum and (ii) warrants to purchase 1,933,066 shares of common stock at an exercise price of \$0.1125 per share. The warrants expire five years from the date of issuance. The securities offered and sold in this private placement were sold in reliance on an exemption from the registration requirements under Regulation D of the Securities Act.

18

Item 6. Exhibits

Exhibit Number	Description
-----	-----
3.1 (1)	Certificate of Incorporation of Astralis Ltd.
3.2 (2)	Bylaws of Astralis Ltd.
4.1 (9)	Specimen Stock Certificate
10.1 (2)	Agreement and Plan of Merger
10.2 (4)	Contribution Agreement dated September 10, 2001
10.3 (5)	Purchase Agreement dated December 10, 2001
10.4 (5)	Stockholder Agreement dated December 10, 2001
10.5 (7)	2001 Stock Option Plan
10.6 (3)	Sub-Lease Agreement
10.7 (3)	License Agreement dated April 26, 2001 between Jose Antonio O'Daly and Astralis LLC
10.8 (3)	Assignment of License
10.9 (3)	Form of Warrant
10.10 (8)	Agreement for Services dated December 10, 2001 between SkyePharma Inc. and Astralis Ltd.
10.11 (8)	Technology Access Option Agreement dated December 10, 2001 by and among SkyePharma Inc., SkyePharma Holding AG and Astralis Ltd.
10.12 (6)	Employment Agreement dated December 10, 2001, between Dr. Jose Antonio O'Daly and Astralis Ltd.
10.13 (6)	Amendment #1 to Agreement for Services dated March 18, 2003 between SkyePharma Inc. and Astralis Ltd.
10.14 (7)	Omnibus Conversion Agreement dated January 12, 2004 between Astralis Ltd. and SkyePharma PLC
10.15 (7)	Call Option Agreement dated January 20, 2004 between Astralis Ltd. and SkyePharma PLC
10.16 (7)	Amendment No. 1 to Stockholders Agreement dated January 20, 2004 by and among Astralis Ltd., SkyePharma PLC, Jose Antonio O'Daly, Mike Ajnsztajn, Gaston Liebhaber and Gina Tedesco
10.17 (11)	Securities Purchase Agreement, dated August 17, 2005, by and between Astralis Ltd. and Blue Cedar Limited.
10.18 (11)	Registration Rights Agreement, dated August 17, 2005, by and between Astralis Ltd. and Blue Cedar Limited.
10.19 (11)	Stockholder's Agreement, dated August 17, 2005, by and between Astralis Ltd. and Blue Cedar Limited.
10.20 (11)	Long-term Common Stock Purchase Warrant, issued to Blue

Edgar Filing: ASTRALIS LTD - Form 10QSB

	Cedar Limited by Astralis Ltd.
10.21 (11)	Short-term Common Stock Purchase Warrant, issued to Blue Cedar Limited by Astralis Ltd.
10.22 (11)	Long-term Common Stock Purchase Warrant, issued to Lipworth Capital Limited by Astralis Ltd.
10.23 (12)	Separation Agreement and General Release, dated January 25, by and between James Sharpe and the Registrant.
10.24 (13)	Form of Subscription Agreement, dated March 31, 2006, by and between Astralis Ltd. and Blue Cedar Limited.
10.25 (13)	Form of Warrant, dated March 31, 2006, issued to Blue Cedar Limited by Astralis Ltd.
10.26 (13)	Form of Convertible Promissory Note in the principal amount of \$250,000, dated March 31, 2006, issued to Blue Cedar Limited by Astralis Ltd.
10.27	Form of Subscription Agreement, dated June 15, 2006 by and between Astralis Ltd and Manuel Tarabay.
10.28	Form of Warrant dated June 15, 2006 issued to Manuel Tarabay by Astralis Ltd.
10.29	Form of Convertible Promissory Note, dated June 15, 2006 issued to Manuel Tarabay by Astralis Ltd.
10.30	Form of Subscription Agreement used in the August 2006 private placement.
10.31	Form of Warrant used in the August 2006 private placement.
10.32	Form of Convertible Promissory Note used in the August 2006 private placement.
14.1 (1)	Code of Ethics for Chief Executive Officer and Senior Financial Officers

=====

19

31.1	Certification by the Interim Chief Executive Officer and the Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1	Certification pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

(1) Previously filed with the Securities and Exchange Commission as an Exhibit to the Annual Report on Form 10-KSB on March 30, 2004.

(2) Previously filed with the Securities and Exchange Commission as an Exhibit to the Preliminary Proxy Statement for Astralis Pharmaceuticals Ltd. on November 16, 2001.

(3) Previously filed with the Securities and Exchange Commission as an Exhibit to the Registration Statement on Form SB-2 for Astralis Ltd. on March 14, 2002.

(4) Previously filed with the Securities and Exchange Commission as an Exhibit to the Current Report on Form 8-K for Astralis Pharmaceuticals Ltd. on November 14, 2001.

(5) Previously filed with the Securities and Exchange Commission as an Exhibit to the Current Report on Form 8-K for Astralis Ltd. on December 14, 2001.

(6) Previously filed with the Securities and Exchange Commission as an Exhibit to the Annual Report on Form 10-KSB on June 30, 2003.

Edgar Filing: ASTRALIS LTD - Form 10QSB

(7) Previously filed with the Securities and Exchange Commission as an Exhibit to the Preliminary Proxy Statement for Hercules Development Group Inc. on October 4, 2001.

(8) Previously filed with the Securities and Exchange Commission as an Exhibit to the Amendment to the Registration Statement on Form SB-2 for Astralis Ltd. on July 23, 2002.

(9) Previously filed with the Securities and Exchange Commission as an Exhibit to the Registration Statement on Form SB-2 for Astralis Ltd. on May 28, 2004.

(10) Previously filed with the Securities and Exchange Commission as an Exhibit to the Registration Statement on Form SB-2 for Astralis Ltd. on June 28, 2004.

(11) Previously filed with the Securities and Exchange Commission as an Exhibit on Form 10-QSB on August 19, 2005.

(12) Previously filed with the Securities and Exchange Commission as an Exhibit on Form 8-K on March 30, 2006.

(13) Previously filed with the Securities and Exchange Commission as an Exhibit on Form 8-K on April 6, 2006.

=====

20

SIGNATURES

In accordance with the requirements of the Securities Exchange Act of 1934, as amended, the Registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

ASTRALIS LTD.
(Registrant)

Dated: August 21, 2006

By: /s/ Michael Garone

Michael Garone
Interim Chief Executive Officer & Chief
Financial Officer (Principal Executive
Officer; Principal Financial and
Accounting Officer, Authorized Signatory
on behalf of Registrant)

=====

21